GlassScriptPhysician profile
Laszlo Sandor Tomaschek
NPI 1962435693
$2,982.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $44.06 · 2021: $13.71 · 2022: $184 · 2023: $733 · 2024: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $791.16 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $543.61 | 2019-2021 | |
| Amgen INC. | $382.22 | 2024 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $363.12 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $244.91 | 2019-2023 | Cequa |
| Horizon Therapeutics Plc | $231.40 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $124.34 | 2019 | |
| Abbvie INC. | $102.16 | 2023-2024 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.42 | 2019 | |
| Oyster Point Pharma, INC. | $41.69 | 2022-2023 | Tyrvaya |
| Alcon Vision LLC | $18.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.84 | 2020 | |
| Rayner Intraocular Lenses Limited | $11.67 | 2022 | |
| Omeros Corporation | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laszlo Tomaschek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.